How Piramal Plans To Scale Up In Critical Care, Build On Acquisitions
Peter DeYoung, CEO of Piramal Critical Care, expects to build “profitable growth positions” from the injectable products acquired from Janssen. He is also upbeat about the commercialization prospects in Europe for intrathecal baclofen and the potential launch of the first desflurane generic in the US.
You may also be interested in...
Peter DeYoung, CEO of Piramal Critical Care
United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.